- RecruitingNA
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
This study looks at how high blood sugar and the antibiotic moxifloxacin affect the heart's electrical rhythm in people with type 2 diabetes. Researchers want to see if moxifloxacin's effect on heart rhythm is worse when blood sugar is high or insulin is low, to improve patient safety.
For: Diabetes Type 2 · Hyperglycaemia (Diabetic) · QT Interval, Variation inUnited Kingdom - RecruitingNA
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
This study looks into how a sugar called fructose might affect people with MASH, a liver condition. Researchers will compare fructose to another sugar, glucose, over four weeks to see if it causes more inflammation or affects liver fat in people with MASH compared to those with less severe liver issues or healthy people.
For: MASH - Metabolic Dysfunction-Associated Steatohepatitis · MASH With Fibrosis · Steatosis of LiverUnited Kingdom - RecruitingNA
Effect of a Sugar Replacement on Blood Glucose Levels in Healthy Adults
This study looks at how a sugar replacement, Oligomate®, affects blood sugar after eating. High blood sugar can be a risk for heart concerns and diabetes. We're testing if Oligomate® can help keep blood sugar levels steady in healthy people.
For: Postprandial Hyperglycemia · HyperinsulinemiaUnited Kingdom - Ongoing, recruitingTherapeutic use (Phase IV)
InSaKa trial: Insulin dextrose infusion versus nebulized salbutamol versus combination of salbutamol and insulin dextrose in acute hyperkalemia: a randomized clinical trial
This study, called InSaKa, is looking at the best way to treat a condition called hyperkalemia, where there's too much potassium in the blood. It compares different treatments, including insulin and dextrose, a breathing treatment called salbutamol, and a combination of both, to see which works best and is safest.
For: HyperkalemiaFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Comorbidity
This study is looking at a new combination of medicines (AZD9550 and AZD6234) for people who are overweight or have obesity and other health problems. Researchers want to see if these medicines help with weight loss and if they are safe to use.
For: Investigating obesity or overweight condition correlated to many co-morbiditiesGermany